-
Study aim
-
Investigating the effect of platelet-rich plasma in the treatment of female androgenetic alopecia
-
Design
-
Clinical trial with control group, with parallel groups, randomized, phase 3 on 60 patients. Block randomization is used for randomization.
-
Settings and conduct
-
The study is conducted on patients with moderate to severe androgenetic alopecia who refer to the medical centers of Isfahan University of Medical Sciences. After examination, obtaining history and consent, patients who meet the inclusion criteria are randomly divided into two groups. The control group receives 5% topical minoxidil daily, and the intervention group, in addition to the mentioned treatment, is treated with platelet-rich plasma for 3 sessions with one-month intervals. After 6 months from the start of the treatment, the patients are compared and evaluated by means of standard photography and trichogram done at the beginning and end of the treatment.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: 1. Patients who are willing to participate in the study. 2. Confirmatory diagnosis of androgenetic alopecia disease by two experts with skin and hair experience. 3. Women aged 18 to 60 years.4. Moderate to severe hair loss.
Criteria for not entering the study: 1. Patients suffering from other types of alopecia (such as alopecia areata, telogen effluvium, anagen effluvium and scarring alopecias). 2. Patients with active psoriasis or active lichen planus due to the positive Köbner phenomenon in these diseases. 3. Any serious systemic disease
-
Intervention groups
-
The control group receives topical minoxidil, and in the intervention group, in addition to the mentioned case, they are also treated with platelet-rich plasma.
-
Main outcome variables
-
Hair thickness, hair density, change of photography score, patient satisfaction